The role of microRNAs in melanoma

European Journal of Cell Biology

Volumn 93, Issue 1-2, 2014, Pages 11-22

  Luo, Chonglin ^a   Weber, Claudia E M ^a   Osen, Wolfram ^a   Bosserhoff, Anja Katrin ^b   Eichmüller, Stefan B ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b UNIVERSITY OF REGENSBURG   (Germany)

Author keywords

Bioinformatics; Diagnosis; Expression profiling; Melanoma; MicroRNA; Oncogene; Target identification; Therapy; Tumor marker; Tumor suppressor

Indexed keywords

MICRORNA; MICRORNA 101; MICRORNA 124A; MICRORNA 125B; MICRORNA 126; MICRORNA 137; MICRORNA 149; MICRORNA 155; MICRORNA 15A; MICRORNA 16; MICRORNA 182; MICRORNA 18B; MICRORNA 196A; MICRORNA 200; MICRORNA 200C; MICRORNA 21; MICRORNA 211; MICRORNA 214; MICRORNA 221; MICRORNA 222; MICRORNA 26A; MICRORNA 29; MICRORNA 30B; MICRORNA 30D; MICRORNA 31; MICRORNA 34; MICRORNA 34B; MICRORNA 375; MICRORNA 768 3P; TRANSCRIPTION FACTOR E2F1; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; TUMOR MARKER;

APOPTOSIS; BREAST CANCER; CANCER CELL CULTURE; CANCER INHIBITION; CANCER PROGNOSIS; CELL ACTIVATION; CELL DIFFERENTIATION; CELL GROWTH; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CHROMOSOME ABERRATION; CUTANEOUS MELANOMA; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; MELANOCYTE; MELANOCYTIC NEVUS; MELANOMA; MELANOMA CELL; METASTASIS; METASTATIC MELANOMA; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SHORT SURVEY; THYROID CARCINOMA; ANIMAL; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PROGNOSIS; SKIN NEOPLASMS; TUMOR SUPPRESSOR GENE;

ANIMALS; ANTINEOPLASTIC AGENTS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, TUMOR SUPPRESSOR; HUMANS; MELANOMA; MICRORNAS; ONCOGENES; PROGNOSIS; SKIN NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84897495796     PISSN: 01719335     EISSN: 16181298     Source Type: Journal    
DOI: 10.1016/j.ejcb.2014.02.001     Document Type: Short Survey

References (148)

1. Asangani I.A., Harms P.W., Dodson L., Pandhi M., Kunju L.P., Maher C.A., Fullen D.R., Johnson T.M., Giordano T.J., Palanisamy N., Chinnaiyan A.M. Genetic and epigenetic loss of microRNA-31 leads to feed-forward expression of EZH2 in melanoma. Oncotarget 2012, 3:1011-1025.
2. Bader A.G., Brown D., Winkler M. The promise of microRNA replacement therapy. Cancer Res. 2010, 70:7027-7030.
3. Bar-Eli M. Searching for the 'melano-miRs': miR-214 drives melanoma metastasis. EMBO J. 2011, 30:1880-1881.
4. Bartel D.P. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004, 116:281-297.
5. Bartel D.P. MicroRNAs: target recognition and regulatory functions. Cell 2009, 136:215-233.
6. Bartels C.L., Tsongalis G.J. MicroRNAs: novel biomarkers for human cancer. Clin. Chem. 2009, 55:623-631.
7. Bedikian A.Y., Millward M., Pehamberger H., Conry R., Gore M., Trefzer U., Pavlick A.C., DeConti R., Hersh E.M., Hersey P., Kirkwood J.M., Haluska F.G. Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group. J. Clin. Oncol. 2006, 24:4738-4745.
8. Bell R.E., Khaled M., Netanely D., Schubert S., Golan T., Buxbaum A., Janas M.M., Postolsky B., Goldberg M.S., Shamir R., Levy C. Transcription factor/microRNA axis blocks melanoma invasion program by miR-211 targeting NUAK1. J. Invest. Dermatol. 2014, 134:441-451.
9. Bemis L.T., Chen R., Amato C.M., Classen E.H., Robinson S.E., Coffey D.G., Erickson P.F., Shellman Y.G., Robinson W.A. MicroRNA-137 targets microphthalmia-associated transcription factor in melanoma cell lines. Cancer Res. 2008, 68:1362-1368.
10. Blower P.E., Verducci J.S., Lin S., Zhou J., Chung J.H., Dai Z., Liu C.G., Reinhold W., Lorenzi P.L., Kaldjian E.P., Croce C.M., Weinstein J.N., Sadee W. MicroRNA expression profiles for the NCI-60 cancer cell panel. Mol. Cancer Ther. 2007, 6:1483-1491.
11. Braig S., Mueller D.W., Rothhammer T., Bosserhoff A.K. MicroRNA miR-196a is a central regulator of HOX-B7 and BMP4 expression in malignant melanoma. Cell. Mol. Life Sci. 2010, 67:3535-3548.
12. Burk U., Schubert J., Wellner U., Schmalhofer O., Vincan E., Spaderna S., Brabletz T. A reciprocal repression between ZEB1 and members of the miR-200 family promotes EMT and invasion in cancer cells. EMBO Rep. 2008, 9:582-589.
13. Calin G.A., Dumitru C.D., Shimizu M., Bichi R., Zupo S., Noch E., Aldler H., Rattan S., Keating M., Rai K., Rassenti L., Kipps T., Negrini M., Bullrich F., Croce C.M. Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc. Natl. Acad. Sci. U.S.A. 2002, 99:15524-15529.
14. Caramuta S., Egyhazi S., Rodolfo M., Witten D., Hansson J., Larsson C., Lui W.O. MicroRNA expression profiles associated with mutational status and survival in malignant melanoma. J. Invest. Dermatol. 2010, 130:2062-2070.
15. Chang T.C., Wentzel E.A., Kent O.A., Ramachandran K., Mullendore M., Lee K.H., Feldmann G., Yamakuchi M., Ferlito M., Lowenstein C.J., Arking D.E., Beer M.A., Maitra A., Mendell J.T. Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis. Mol. Cell 2007, 26:745-752.
16. Chen J., Feilotter H.E., Pare G.C., Zhang X., Pemberton J.G., Garady C., Lai D., Yang X., Tron V.A. MicroRNA-193b represses cell proliferation and regulates cyclin D1 in melanoma. Am. J. Pathol. 2010, 176:2520-2529.
17. Chen J., Zhang X., Lentz C., Abi-Daoud M., Pare G.C., Yang X., Feilotter H.E., Tron V.A. miR-193b regulates Mcl-1 in melanoma. Am. J. Pathol. 2011, 179:2162-2168.
18. Chen Q., Chen X., Zhang M., Fan Q., Luo S., Cao X. miR-137 is frequently down-regulated in gastric cancer and is a negative regulator of Cdc42. Dig. Dis. Sci. 2011, 56:2009-2016.
19. Chen X., He D., Dong X.D., Dong F., Wang J., Wang L., Tang J., Hu D.N., Yan D., Tu L. MicroRNA-124a is epigenetically regulated and acts as a tumor suppressor by controlling multiple targets in uveal melanoma. Invest. Ophthalmol. Vis. Sci. 2013, 54:2248-2256.
20. Chen X., Wang J., Shen H., Lu J., Li C., Hu D.N., Dong X.D., Yan D., Tu L. Epigenetics, microRNAs, and carcinogenesis: functional role of microRNA-137 in uveal melanoma. Invest. Ophthalmol. Vis. Sci. 2011, 52:1193-1199.
21. Chen Y., Zhu X., Zhang X., Liu B., Huang L. Nanoparticles modified with tumor-targeting scFv deliver siRNA and miRNA for cancer therapy. Mol. Ther. 2010, 18:1650-1656.
22. Cheng A.M., Byrom M.W., Shelton J., Ford L.P. Antisense inhibition of human miRNAs and indications for an involvement of miRNA in cell growth and apoptosis. Nucleic Acids Res. 2005, 33:1290-1297.
23. Cho W.C., Chow A.S., Au J.S. Restoration of tumour suppressor hsa-miR-145 inhibits cancer cell growth in lung adenocarcinoma patients with epidermal growth factor receptor mutation. Eur. J. Cancer 2009, 45:2197-2206.
24. Cortez M.A., Ivan C., Zhou P., Wu X., Ivan M., Calin G.A. microRNAs in cancer: from bench to bedside. Adv. Cancer Res. 2010, 108:113-157.
25. Couts K.L., Anderson E.M., Gross M.M., Sullivan K., Ahn N.G. Oncogenic B-Raf signaling in melanoma cells controls a network of microRNAs with combinatorial functions. Oncogene 2013, 32:1959-1970.
26. Dangi-Garimella S., Yun J., Eves E.M., Newman M., Erkeland S.J., Hammond S.M., Minn A.J., Rosner M.R. Raf kinase inhibitory protein suppresses a metastasis signalling cascade involving LIN28 and let-7. EMBO J. 2009, 28:347-358.
27. Dar A.A., Majid S., Rittsteuer C., de Semir D., Bezrookove V., Tong S., Nosrati M., Sagebiel R., Miller J.R., Kashani-Sabet M. The role of miR-18b in MDM2-p53 pathway signaling and melanoma progression. J. Natl. Cancer Inst. 2013, 105:433-442.
28. Das S.K., Sokhi U.K., Bhutia S.K., Azab B., Su Z.Z., Sarkar D., Fisher P.B. Human polynucleotide phosphorylase selectively and preferentially degrades microRNA-221 in human melanoma cells. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:11948-11953.
29. Deng Y., Deng H., Bi F., Liu J., Bemis L.T., Norris D., Wang X.J., Zhang Q. MicroRNA-137 targets carboxyl-terminal binding protein 1 in melanoma cell lines. Int. J. Biol. Sci. 2011, 7:133-137.
30. Diederichs S., Haber D.A. Dual role for argonautes in microRNA processing and posttranscriptional regulation of microRNA expression. Cell 2007, 131:1097-1108.
31. Eisen T., Ahmad T., Flaherty K.T., Gore M., Kaye S., Marais R., Gibbens I., Hackett S., James M., Schuchter L.M., Nathanson K.L., Xia C., Simantov R., Schwartz B., Poulin-Costello M., O'Dwyer P.J., Ratain M.J. Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis. Br. J. Cancer 2006, 95:581-586.
32. Elson-Schwab I., Lorentzen A., Marshall C.J. MicroRNA-200 family members differentially regulate morphological plasticity and mode of melanoma cell invasion. PLoS ONE 2010, 5.
33. End D.W., Smets G., Todd A.V., Applegate T.L., Fuery C.J., Angibaud P., Venet M., Sanz G., Poignet H., Skrzat S., Devine A., Wouters W., Bowden C. Characterization of the antitumor effects of the selective farnesyl protein transferase inhibitor R115777 in vivo and in vitro. Cancer Res. 2001, 61:131-137.
34. Errico M.C., Felicetti F., Bottero L., Mattia G., Boe A., Felli N., Petrini M., Bellenghi M., Pandha H.S., Calvaruso M., Tripodo C., Colombo M.P., Morgan R., Care A. The abrogation of the HOXB7/PBX2 complex induces apoptosis in melanoma through the miR-221&222-c-FOS pathway. Int. J. Cancer 2013, 133:879-892.
35. Esquela-Kerscher A., Slack F.J. Oncomirs - microRNAs with a role in cancer. Nat. Rev. Cancer 2006, 6:259-269.
36. Felicetti F., Errico M.C., Bottero L., Segnalini P., Stoppacciaro A., Biffoni M., Felli N., Mattia G., Petrini M., Colombo M.P., Peschle C., Care A. The promyelocytic leukemia zinc finger-microRNA-221/-222 pathway controls melanoma progression through multiple oncogenic mechanisms. Cancer Res. 2008, 68:2745-2754.
37. Felli N., Felicetti F., Lustri A.M., Errico M.C., Bottero L., Cannistraci A., De Feo A., Petrini M., Pedini F., Biffoni M., Alvino E., Negrini M., Ferracin M., Mattia G., Care A. miR-126&126* restored expressions play a tumor suppressor role by directly regulating ADAM9 and MMP7 in melanoma. PLoS ONE 2013, 8:e56824.
38. Felli N., Fontana L., Pelosi E., Botta R., Bonci D., Facchiano F., Liuzzi F., Lulli V., Morsilli O., Santoro S., Valtieri M., Calin G.A., Liu C.G., Sorrentino A., Croce C.M., Peschle C. MicroRNAs 221 and 222 inhibit normal erythropoiesis and erythroleukemic cell growth via kit receptor down-modulation. Proc. Natl. Acad. Sci. U.S.A. 2005, 102:18081-18086.
39. Feng R., Chen X., Yu Y., Su L., Yu B., Li J., Cai Q., Yan M., Liu B., Zhu Z. miR-126 functions as a tumour suppressor in human gastric cancer. Cancer Lett. 2010, 298:50-63.
40. Fish J.E., Santoro M.M., Morton S.U., Yu S., Yeh R.F., Wythe J.D., Ivey K.N., Bruneau B.G., Stainier D.Y., Srivastava D. miR-126 regulates angiogenic signaling and vascular integrity. Dev. Cell 2008, 15:272-284.
41. Fu X., Meng Z., Liang W., Tian Y., Wang X., Han W., Lou G., Wang X., Lou F., Yen Y., Yu H., Jove R., Huang W. miR-26a enhances miRNA biogenesis by targeting Lin28B and Zcchc11 to suppress tumor growth and metastasis. Oncogene 2013, 10.1038/onc.2013.385.
42. Galardi S., Mercatelli N., Giorda E., Massalini S., Frajese G.V., Ciafre S.A., Farace M.G. miR-221 and miR-222 expression affects the proliferation potential of human prostate carcinoma cell lines by targeting p27Kip1. J. Biol. Chem. 2007, 282:23716-23724.
43. Garzon R., Heaphy C.E., Havelange V., Fabbri M., Volinia S., Tsao T., Zanesi N., Kornblau S.M., Marcucci G., Calin G.A., Andreeff M., Croce C.M. MicroRNA 29b functions in acute myeloid leukemia. Blood 2009, 114:5331-5341.
44. Gaur A., Jewell D.A., Liang Y., Ridzon D., Moore J.H., Chen C., Ambros V.R., Israel M.A. Characterization of microRNA expression levels and their biological correlates in human cancer cell lines. Cancer Res. 2007, 67:2456-2468.
45. Gaziel-Sovran A., Segura M.F., Di Micco R., Collins M.K., Hanniford D., Vega-Saenz de Miera E., Rakus J.F., Dankert J.F., Shang S., Kerbel R.S., Bhardwaj N., Shao Y., Darvishian F., Zavadil J., Erlebacher A., Mahal L.K., Osman I., Hernando E. miR-30b/30d regulation of GalNAc transferases enhances invasion and immunosuppression during metastasis. Cancer Cell 2011, 20:104-118.
46. Git A., Dvinge H., Salmon-Divon M., Osborne M., Kutter C., Hadfield J., Bertone P., Caldas C. Systematic comparison of microarray profiling, real-time PCR, and next-generation sequencing technologies for measuring differential microRNA expression. RNA 2010, 16:991-1006.
47. Gray-Schopfer V., Wellbrock C., Marais R. Melanoma biology and new targeted therapy. Nature 2007, 445:851-857.
48. Grignol V., Fairchild E.T., Zimmerer J.M., Lesinski G.B., Walker M.J., Magro C.M., Kacher J.E., Karpa V.I., Clark J., Nuovo G., Lehman A., Volinia S., Agnese D.M., Croce C.M., Carson W.E. miR-21 and miR-155 are associated with mitotic activity and lesion depth of borderline melanocytic lesions. Br. J. Cancer 2011, 105:1023-1029.
49. Grund S.E., Polycarpou-Schwarz M., Luo C., Eichmuller S.B., Diederichs S. Rare Drosha splice variants are deficient in microRNA processing but do not affect general microRNA expression in cancer cells. Neoplasia 2012, 14:238-248.
50. Guo C., Sah J.F., Beard L., Willson J.K., Markowitz S.D., Guda K. The noncoding RNA, miR-126, suppresses the growth of neoplastic cells by targeting phosphatidylinositol 3-kinase signaling and is frequently lost in colon cancers. Genes Chromosomes Cancer 2008, 47:939-946.
51. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
52. Hayashita Y., Osada H., Tatematsu Y., Yamada H., Yanagisawa K., Tomida S., Yatabe Y., Kawahara K., Sekido Y., Takahashi T. A polycistronic microRNA cluster, miR-17-92, is overexpressed in human lung cancers and enhances cell proliferation. Cancer Res. 2005, 65:9628-9632.
53. He H., Jazdzewski K., Li W., Liyanarachchi S., Nagy R., Volinia S., Calin G.A., Liu C.G., Franssila K., Suster S., Kloos R.T., Croce C.M., de la Chapelle A. The role of microRNA genes in papillary thyroid carcinoma. Proc. Natl. Acad. Sci. U.S.A. 2005, 102:19075-19080.
54. He L., He X., Lim L.P., de Stanchina E., Xuan Z., Liang Y., Xue W., Zender L., Magnus J., Ridzon D., Jackson A.L., Linsley P.S., Chen C., Lowe S.W., Cleary M.A., Hannon G.J. A microRNA component of the p53 tumour suppressor network. Nature 2007, 447:1130-1134.
55. Hermeking H. The miR-34 family in cancer and apoptosis. Cell Death Differ. 2010, 17:193-199.
56. Huynh C., Segura M.F., Gaziel-Sovran A., Menendez S., Darvishian F., Chiriboga L., Levin B., Meruelo D., Osman I., Zavadil J., Marcusson E.G., Hernando E. Efficient in vivo microRNA targeting of liver metastasis. Oncogene 2011, 30:1481-1488.
57. Iorio M.V., Croce C.M. microRNA involvement in human cancer. Carcinogenesis 2012, 33:1126-1133.
58. Iorio M.V., Piovan C., Croce C.M. Interplay between microRNAs and the epigenetic machinery: an intricate network. Biochim. Biophys. Acta 2010, 1799:694-701.
59. Izumiya M., Okamoto K., Tsuchiya N., Nakagama H. Functional screening using a microRNA virus library and microarrays: a new high-throughput assay to identify tumor-suppressive microRNAs. Carcinogenesis 2010, 31:1354-1359.
60. Jafarnejad S.M., Ardekani G.S., Ghaffari M., Martinka M., Li G. Sox4-mediated Dicer expression is critical for suppression of melanoma cell invasion. Oncogene 2013, 32:2131-2139.
61. Jafarnejad S.M., Sjoestroem C., Martinka M., Li G. Expression of the RNase III enzyme DROSHA is reduced during progression of human cutaneous melanoma. Mod. Pathol. 2013, 26:902-910.
62. Jiang C.C., Croft A., Tseng H.Y., Guo S.T., Jin L., Hersey P., Zhang X.D. Repression of microRNA-768-3p by MEK/ERK signalling contributes to enhanced mRNA translation in human melanoma. Oncogene 2013, 10.1038/onc.2013.237.
63. Jin L., Hu W.L., Jiang C.C., Wang J.X., Han C.C., Chu P., Zhang L.J., Thorne R.F., Wilmott J., Scolyer R.A., Hersey P., Zhang X.D., Wu M. MicroRNA-149*, a p53-responsive microRNA, functions as an oncogenic regulator in human melanoma. Proc. Natl. Acad. Sci. U.S.A. 2011, 108:15840-15845.
64. Johnson S.M., Grosshans H., Shingara J., Byrom M., Jarvis R., Cheng A., Labourier E., Reinert K.L., Brown D., Slack F.J. RAS is regulated by the let-7 microRNA family. Cell 2005, 120:635-647.
65. Jukic D.M., Rao U.N., Kelly L., Skaf J.S., Drogowski L.M., Kirkwood J.M., Panelli M.C. Microrna profiling analysis of differences between the melanoma of young adults and older adults. J. Transl. Med. 2010, 8:27.
66. Kanemaru H., Fukushima S., Yamashita J., Honda N., Oyama R., Kakimoto A., Masuguchi S., Ishihara T., Inoue Y., Jinnin M., Ihn H. The circulating microRNA-221 level in patients with malignant melanoma as a new tumor marker. J. Dermatol. Sci. 2011, 61:187-193.
67. Kappelmann M., Kuphal S., Meister G., Vardimon L., Bosserhoff A.K. MicroRNA miR-125b controls melanoma progression by direct regulation of c-Jun protein expression. Oncogene 2013, 32:2984-2991.
68. Kozubek J., Ma Z., Fleming E., Duggan T., Wu R., Shin D.G., Dadras S.S. In-depth characterization of microRNA transcriptome in melanoma. PLoS ONE 2013, 8:e72699.
69. Krek A., Grun D., Poy M.N., Wolf R., Rosenberg L., Epstein E.J., MacMenamin P., da Piedade I., Gunsalus K.C., Stoffel M., Rajewsky N. Combinatorial microRNA target predictions. Nat. Genet. 2005, 37:495-500.
70. Krol J., Loedige I., Filipowicz W. The widespread regulation of microRNA biogenesis, function and decay. Nat. Rev. Genet. 2010, 11:597-610.
71. Kunz M. MicroRNAs in melanoma biology. Adv. Exp. Med. Biol. 2013, 774:103-120.
72. Lam L.T., Lu X., Zhang H., Lesniewski R., Rosenberg S., Semizarov D. A microRNA screen to identify modulators of sensitivity to BCL2 inhibitor ABT-263 (navitoclax). Mol. Cancer Ther. 2010, 9:2943-2950.
73. Langevin S.M., Stone R.A., Bunker C.H., Lyons-Weiler M.A., Laframboise W.A., Kelly L., Seethala R.R., Grandis J.R., Sobol R.W., Taioli E. MicroRNA-137 promoter methylation is associated with poorer overall survival in patients with squamous cell carcinoma of the head and neck. Cancer 2011, 117:1454-1462.
74. le Sage C., Nagel R., Egan D.A., Schrier M., Mesman E., Mangiola A., Anile C., Maira G., Mercatelli N., Ciafre S.A., Farace M.G., Agami R. Regulation of the p27(Kip1) tumor suppressor by miR-221 and miR-222 promotes cancer cell proliferation. EMBO J. 2007, 26:3699-3708.
75. Lee E.J., Gusev Y., Jiang J., Nuovo G.J., Lerner M.R., Frankel W.L., Morgan D.L., Postier R.G., Brackett D.J., Schmittgen T.D. Expression profiling identifies microRNA signature in pancreatic cancer. Int. J. Cancer 2007, 120:1046-1054.
76. Leidinger P., Keller A., Borries A., Reichrath J., Rass K., Jager S.U., Lenhof H.P., Meese E. High-throughput miRNA profiling of human melanoma blood samples. BMC Cancer 2010, 10:262.
77. Levati L., Alvino E., Pagani E., Arcelli D., Caporaso P., Bondanza S., Di Leva G., Ferracin M., Volinia S., Bonmassar E., Croce C.M., D'Atri S. Altered expression of selected microRNAs in melanoma: antiproliferative and proapoptotic activity of miRNA-155. Int. J. Oncol. 2009, 35:393-400.
78. Levati L., Pagani E., Romani S., Castiglia D., Piccinni E., Covaciu C., Caporaso P., Bondanza S., Antonetti F.R., Bonmassar E., Martelli F., Alvino E., D'Atri S. MicroRNA-155 targets the SKI gene in human melanoma cell lines. Pigment Cell Melanoma Res. 2011, 24:538-550.
79. Levy C., Khaled M., Iliopoulos D., Janas M.M., Schubert S., Pinner S., Chen P.H., Li S., Fletcher A.L., Yokoyama S., Scott K.L., Garraway L.A., Song J.S., Granter S.R., Turley S.J., Fisher D.E., Novina C.D. Intronic miR-211 assumes the tumor suppressive function of its host gene in melanoma. Mol. Cell 2010, 40:841-849.
80. Liu M., Lang N., Qiu M., Xu F., Li Q., Tang Q., Chen J., Chen X., Zhang S., Liu Z., Zhou J., Zhu Y., Deng Y., Zheng Y., Bi F. miR-137 targets Cdc42 expression, induces cell cycle G1 arrest and inhibits invasion in colorectal cancer cells. Int. J. Cancer 2011, 128:1269-1279.
81. Liu S., Tetzlaff M.T., Cui R., Xu X. miR-200c inhibits melanoma progression and drug resistance through down-regulation of BMI-1. Am. J. Pathol. 2012, 181:1823-1835.
82. Lodygin D., Tarasov V., Epanchintsev A., Berking C., Knyazeva T., Korner H., Knyazev P., Diebold J., Hermeking H. Inactivation of miR-34a by aberrant CpG methylation in multiple types of cancer. Cell Cycle 2008, 7:2591-2600.
83. Lu J., Getz G., Miska E.A., Alvarez-Saavedra E., Lamb J., Peck D., Sweet-Cordero A., Ebert B.L., Mak R.H., Ferrando A.A., Downing J.R., Jacks T., Horvitz H.R., Golub T.R. MicroRNA expression profiles classify human cancers. Nature 2005, 435:834-838.
84. Luo C., Merz P.R., Chen Y., Dickes E., Pscherer A., Schadendorf D., Eichmüller S.B. MiR-101 inhibits melanoma cell invasion and proliferation by targeting MITF and EZH2. Cancer Lett. 2013, 341:240-247.
85. Luo C., Tetteh P.W., Merz P.R., Dickes E., Abukiwan A., Hotz-Wagenblatt A., Holland-Cunz S., Sinnberg T., Schittek B., Schadendorf D., Diederichs S., Eichmüller S.B. miR-137 inhibits the invasion of melanoma cells through downregulation of multiple oncogenic target genes. J. Invest. Dermatol. 2013, 133:768-775.
86. Mattia G., Errico M.C., Felicetti F., Petrini M., Bottero L., Tomasello L., Romania P., Boe A., Segnalini P., Di Virgilio A., Colombo M.P., Care A. Constitutive activation of the ETS-1-miR-222 circuitry in metastatic melanoma. Pigment Cell Melanoma Res. 2011, 24:953-965.
87. Mazar J., DeBlasio D., Govindarajan S.S., Zhang S., Perera R.J. Epigenetic regulation of microRNA-375 and its role in melanoma development in humans. FEBS Lett. 2011, 585:2467-2476.
88. Mazar J., DeYoung K., Khaitan D., Meister E., Almodovar A., Goydos J., Ray A., Perera R.J. The regulation of miRNA-211 expression and its role in melanoma cell invasiveness. PLoS ONE 2010, 5:e13779.
89. Mazar J., Khaitan D., DeBlasio D., Zhong C., Govindarajan S.S., Kopanathi S., Zhang S., Ray A., Perera R.J. Epigenetic regulation of microRNA genes and the role of miR-34b in cell invasion and motility in human melanoma. PLoS ONE 2011, 6:e24922.
90. Meister J., Schmidt M.H. miR-126 and miR-126*: new players in cancer. Sci. World J. 2010, 10:2090-2100.
91. Mendell J.T. miRiad roles for the miR-17-92 cluster in development and disease. Cell 2008, 133:217-222.
92. Mitchell P.S., Parkin R.K., Kroh E.M., Fritz B.R., Wyman S.K., Pogosova-Agadjanyan E.L., Peterson A., Noteboom J., O'Briant K.C., Allen A., Lin D.W., Urban N., Drescher C.W., Knudsen B.S., Stirewalt D.L., Gentleman R., Vessella R.L., Nelson P.S., Martin D.B., Tewari M. Circulating microRNAs as stable blood-based markers for cancer detection. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:10513-10518.
93. Montone K.T., van Belle P., Elenitsas R., Elder D.E. Proto-oncogene c-kit expression in malignant melanoma: protein loss with tumor progression. Mod. Pathol. 1997, 10:939-944.
94. Mueller D.W., Bosserhoff A.K. MicroRNA miR-196a controls melanoma-associated genes by regulating HOX-C8 expression. Int. J. Cancer 2011, 129:1064-1074.
95. Mueller D.W., Rehli M., Bosserhoff A.K. miRNA expression profiling in melanocytes and melanoma cell lines reveals miRNAs associated with formation and progression of malignant melanoma. J. Invest. Dermatol. 2009, 129:1740-1751.
96. Muller D.W., Bosserhoff A.K. Integrin beta 3 expression is regulated by let-7a miRNA in malignant melanoma. Oncogene 2008, 27:6698-6706.
97. Musiyenko A., Bitko V., Barik S. Ectopic expression of miR-126*, an intronic product of the vascular endothelial EGF-like 7 gene, regulates prostein translation and invasiveness of prostate cancer LNCaP cells. J. Mol. Med. 2008, 86:313-322.
98. Nakamura T., Canaani E., Croce C.M. Oncogenic All1 fusion proteins target Drosha-mediated microRNA processing. Proc. Natl. Acad. Sci. U.S.A. 2007, 104:10980-10985.
99. Nemlich Y., Greenberg E., Ortenberg R., Besser M.J., Barshack I., Jacob-Hirsch J., Jacoby E., Eyal E., Rivkin L., Prieto V.G., Chakravarti N., Duncan L.M., Kallenberg D.M., Galun E., Bennett D.C., Amariglio N., Bar-Eli M., Schachter J., Rechavi G., Markel G. MicroRNA-mediated loss of ADAR1 in metastatic melanoma promotes tumor growth. J. Clin. Invest. 2013, 123:2703-2718.
100. Nicoli S., Standley C., Walker P., Hurlstone A., Fogarty K.E., Lawson N.D. MicroRNA-mediated integration of haemodynamics and Vegf signalling during angiogenesis. Nature 2010, 464:1196-1200.
101. O'Donnell K.A., Wentzel E.A., Zeller K.I., Dang C.V., Mendell J.T. c-Myc-regulated microRNAs modulate E2F1 expression. Nature 2005, 435:839-843.
102. Ota A., Tagawa H., Karnan S., Tsuzuki S., Karpas A., Kira S., Yoshida Y., Seto M. Identification and characterization of a novel gene, C13orf25, as a target for 13q31-q32 amplification in malignant lymphoma. Cancer Res. 2004, 64:3087-3095.
103. Ovcharenko D., Kelnar K., Johnson C., Leng N., Brown D. Genome-scale microRNA and small interfering RNA screens identify small RNA modulators of TRAIL-induced apoptosis pathway. Cancer Res. 2007, 67:10782-10788.
104. Penna E., Orso F., Cimino D., Tenaglia E., Lembo A., Quaglino E., Poliseno L., Haimovic A., Osella-Abate S., De Pitta C., Pinatel E., Stadler M.B., Provero P., Bernengo M.G., Osman I., Taverna D. microRNA-214 contributes to melanoma tumour progression through suppression of TFAP2C. EMBO J. 2011, 30:1990-2007.
105. Penna E., Orso F., Cimino D., Vercellino I., Grassi E., Quaglino E., Turco E., Taverna D. miR-214 coordinates melanoma progression by upregulating ALCAM through TFAP2 and miR-148b downmodulation. Cancer Res. 2013, 73:4098-4111.
106. Perera R.J., Ray A. Epigenetic regulation of miRNA genes and their role in human melanomas. Epigenomics 2012, 4:81-90.
107. Philippidou D., Schmitt M., Moser D., Margue C., Nazarov P.V., Muller A., Vallar L., Nashan D., Behrmann I., Kreis S. Signatures of microRNAs and selected microRNA target genes in human melanoma. Cancer Res. 2010, 70:4163-4173.
108. Poell J.B., van Haastert R.J., de Gunst T., Schultz I.J., Gommans W.M., Verheul M., Cerisoli F., van Noort P.I., Prevost G.P., Schaapveld R.Q., Cuppen E. A functional screen identifies specific microRNAs capable of inhibiting human melanoma cell viability. PLoS ONE 2012, 7:e43569.
109. Pradervand S., Weber J., Lemoine F., Consales F., Paillusson A., Dupasquier M., Thomas J., Richter H., Kaessmann H., Beaudoing E., Hagenbuchle O., Harshman K. Concordance among digital gene expression, microarrays, and qPCR when measuring differential expression of microRNAs. Biotechniques 2010, 48:219-222.
110. Raver-Shapira N., Marciano E., Meiri E., Spector Y., Rosenfeld N., Moskovits N., Bentwich Z., Oren M. Transcriptional activation of miR-34a contributes to p53-mediated apoptosis. Mol. Cell 2007, 26:731-743.
111. Reinsbach S., Nazarov P.V., Philippidou D., Schmitt M., Wienecke-Baldacchino A., Muller A., Vallar L., Behrmann I., Kreis S. Dynamic regulation of microRNA expression following interferon-gamma-induced gene transcription. RNA Biol. 2012, 9:978-989.
112. Saito Y., Friedman J.M., Chihara Y., Egger G., Chuang J.C., Liang G. Epigenetic therapy upregulates the tumor suppressor microRNA-126 and its host gene EGFL7 in human cancer cells. Biochem. Biophys. Res. Commun. 2009, 379:726-731.
113. Sand M., Skrygan M., Sand D., Georgas D., Gambichler T., Hahn S.A., Altmeyer P., Bechara F.G. Comparative microarray analysis of microRNA expression profiles in primary cutaneous malignant melanoma, cutaneous malignant melanoma metastases, and benign melanocytic nevi. Cell Tissue Res. 2013, 351:85-98.
114. Satzger I., Mattern A., Kuettler U., Weinspach D., Niebuhr M., Kapp A., Gutzmer R. microRNA-21 is upregulated in malignant melanoma and influences apoptosis of melanocytic cells. Exp. Dermatol. 2012, 21:509-514.
115. Satzger I., Mattern A., Kuettler U., Weinspach D., Voelker B., Kapp A., Gutzmer R. MicroRNA-15b represents an independent prognostic parameter and is correlated with tumor cell proliferation and apoptosis in malignant melanoma. Int. J. Cancer 2010, 126:2553-2562.
116. Schmitt M.J., Philippidou D., Reinsbach S.E., Margue C., Wienecke-Baldacchino A., Nashan D., Behrmann I., Kreis S. Interferon-gamma-induced activation of signal transducer and activator of transcription 1 (STAT1) up-regulates the tumor suppressing microRNA-29 family in melanoma cells. Cell Commun. Signal. 2012, 10:41.
117. Schultz J., Lorenz P., Gross G., Ibrahim S., Kunz M. MicroRNA let-7b targets important cell cycle molecules in malignant melanoma cells and interferes with anchorage-independent growth. Cell Res. 2008, 18:549-557.
118. Segura M.F., Belitskaya-Levy I., Rose A.E., Zakrzewski J., Gaziel A., Hanniford D., Darvishian F., Berman R.S., Shapiro R.L., Pavlick A.C., Osman I., Hernando E. Melanoma microRNA signature predicts post-recurrence survival. Clin. Cancer Res. 2010, 16:1577-1586.
119. Segura M.F., Hanniford D., Menendez S., Reavie L., Zou X., Alvarez-Diaz S., Zakrzewski J., Blochin E., Rose A., Bogunovic D., Polsky D., Wei J., Lee P., Belitskaya-Levy I., Bhardwaj N., Osman I., Hernando E. Aberrant miR-182 expression promotes melanoma metastasis by repressing FOXO3 and microphthalmia-associated transcription factor. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:1814-1819.
120. Shen S.S., Zhang P.S., Eton O., Prieto V.G. Analysis of protein tyrosine kinase expression in melanocytic lesions by tissue array. J. Cutan. Pathol. 2003, 30:539-547.
121. Silber J., Lim D.A., Petritsch C., Persson A.I., Maunakea A.K., Yu M., Vandenberg S.R., Ginzinger D.G., James C.D., Costello J.F., Bergers G., Weiss W.A., Alvarez-Buylla A., Hodgson J.G. miR-124 and miR-137 inhibit proliferation of glioblastoma multiforme cells and induce differentiation of brain tumor stem cells. BMC Med. 2008, 6:14.
122. Sita-Lumsden A., Dart D.A., Waxman J., Bevan C.L. Circulating microRNAs as potential new biomarkers for prostate cancer. Br. J. Cancer 2013, 108:1925-1930.
123. Smits M., Nilsson J., Mir S.E., van der Stoop P.M., Hulleman E., Niers J.M., de Witt Hamer P.C., Marquez V.E., Cloos J., Krichevsky A.M., Noske D.P., Tannous B.A., Wurdinger T. miR-101 is down-regulated in glioblastoma resulting in EZH2-induced proliferation, migration, and angiogenesis. Oncotarget 2010, 1:710-720.
124. Soncin F., Mattot V., Lionneton F., Spruyt N., Lepretre F., Begue A., Stehelin D. VE-statin, an endothelial repressor of smooth muscle cell migration. EMBO J. 2003, 22:5700-5711.
125. Stark M.S., Tyagi S., Nancarrow D.J., Boyle G.M., Cook A.L., Whiteman D.C., Parsons P.G., Schmidt C., Sturm R.A., Hayward N.K. Characterization of the melanoma miRNAome by deep sequencing. PLoS ONE 2010, 5:e9685.
126. Suzuki H.I., Yamagata K., Sugimoto K., Iwamoto T., Kato S., Miyazono K. Modulation of microRNA processing by p53. Nature 2009, 460:529-533.
127. Takamizawa J., Konishi H., Yanagisawa K., Tomida S., Osada H., Endoh H., Harano T., Yatabe Y., Nagino M., Nimura Y., Mitsudomi T., Takahashi T. Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival. Cancer Res. 2004, 64:3753-3756.
128. Talotta F., Cimmino A., Matarazzo M.R., Casalino L., De Vita G., D'Esposito M., Di Lauro R., Verde P. An autoregulatory loop mediated by miR-21 and PDCD4 controls the AP-1 activity in RAS transformation. Oncogene 2009, 28:73-84.
129. Tarasov V., Jung P., Verdoodt B., Lodygin D., Epanchintsev A., Menssen A., Meister G., Hermeking H. Differential regulation of microRNAs by p53 revealed by massively parallel sequencing: miR-34a is a p53 target that induces apoptosis and G1-arrest. Cell Cycle 2007, 6:1586-1593.
130. Tavazoie S.F., Alarcon C., Oskarsson T., Padua D., Wang Q., Bos P.D., Gerald W.L., Massague J. Endogenous human microRNAs that suppress breast cancer metastasis. Nature 2008, 451:147-152.
131. Tucker G.C. Integrins: molecular targets in cancer therapy. Curr. Oncol. Rep. 2006, 8:96-103.
132. van Kempen L.C., van den Hurk K., Lazar V., Michiels S., Winnepenninckx V., Stas M., Spatz A., van den Oord J.J. Loss of microRNA-200a and c, and microRNA-203 expression at the invasive front of primary cutaneous melanoma is associated with increased thickness and disease progression. Virchows Arch. 2012, 461:441-448.
133. Varambally S., Cao Q., Mani R.S., Shankar S., Wang X., Ateeq B., Laxman B., Cao X., Jing X., Ramnarayanan K., Brenner J.C., Yu J., Kim J.H., Han B., Tan P., Kumar-Sinha C., Lonigro R.J., Palanisamy N., Maher C.A., Chinnaiyan A.M. Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer. Science 2008, 322:1695-1699.
134. Vasilatou D., Papageorgiou S., Pappa V., Papageorgiou E., Dervenoulas J. The role of microRNAs in normal and malignant hematopoiesis. Eur. J. Haematol. 2010, 84:1-16.
135. Ventura A., Jacks T. MicroRNAs and cancer: short RNAs go a long way. Cell 2009, 136:586-591.
136. Volinia S., Calin G.A., Liu C.G., Ambs S., Cimmino A., Petrocca F., Visone R., Iorio M., Roldo C., Ferracin M., Prueitt R.L., Yanaihara N., Lanza G., Scarpa A., Vecchione A., Negrini M., Harris C.C., Croce C.M. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc. Natl. Acad. Sci. U.S.A. 2006, 103:2257-2261.
137. Voller D., Ott C., Bosserhoff A. MicroRNAs in malignant melanoma. Clin. Biochem. 2013, 46:909-917.
138. von Brandenstein M., Depping R., Schafer E., Dienes H.P., Fries J.W. Protein kinase C alpha regulates nuclear pri-microRNA 15a release as part of endothelin signaling. Biochim. Biophys. Acta 2011, 1813:1793-1802.
139. Wang H.J., Ruan H.J., He X.J., Ma Y.Y., Jiang X.T., Xia Y.J., Ye Z.Y., Tao H.Q. MicroRNA-101 is down-regulated in gastric cancer and involved in cell migration and invasion. Eur. J. Cancer 2010, 46:2295-2303.
140. Wang X., Tang S., Le S.Y., Lu R., Rader J.S., Meyers C., Zheng Z.M. Aberrant expression of oncogenic and tumor-suppressive microRNAs in cervical cancer is required for cancer cell growth. PLoS ONE 2008, 3:e2557.
141. Weinstein I.B., Joe A. Oncogene addiction. Cancer Res. 2008, 68:3077-3080. discussion 3080.
142. Winter J., Jung S., Keller S., Gregory R.I., Diederichs S. Many roads to maturity: microRNA biogenesis pathways and their regulation. Nat. Cell Biol. 2009, 11:228-234.
143. Wu W. MicroRNA: potential targets for the development of novel drugs?. Drugs R. D. 2010, 10:1-8.
144. Xu Y., Brenn T., Brown E.R., Doherty V., Melton D.W. Differential expression of microRNAs during melanoma progression: miR-200c, miR-205 and miR-211 are downregulated in melanoma and act as tumour suppressors. Br. J. Cancer 2012, 106:553-561.
145. Yaguchi S., Fukui Y., Koshimizu I., Yoshimi H., Matsuno T., Gouda H., Hirono S., Yamazaki K., Yamori T. Antitumor activity of ZSTK474, a new phosphatidylinositol 3-kinase inhibitor. J. Natl. Cancer Inst. 2006, 98:545-556.
146. Yanaihara N., Caplen N., Bowman E., Seike M., Kumamoto K., Yi M., Stephens R.M., Okamoto A., Yokota J., Tanaka T., Calin G.A., Liu C.G., Croce C.M., Harris C.C. Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell 2006, 9:189-198.
147. Zhang J.G., Guo J.F., Liu D.L., Liu Q., Wang J.J. MicroRNA-101 exerts tumor-suppressive functions in non-small cell lung cancer through directly targeting enhancer of zeste homolog 2. J. Thorac. Oncol. 2011, 6:671-678.
148. Zhang L., Huang J., Yang N., Greshock J., Megraw M.S., Giannakakis A., Liang S., Naylor T.L., Barchetti A., Ward M.R., Yao G., Medina A., O'Brien-Jenkins A., Katsaros D., Hatzigeorgiou A., Gimotty P.A., Weber B.L., Coukos G. microRNAs exhibit high frequency genomic alterations in human cancer. Proc. Natl. Acad. Sci. U.S.A. 2006, 103:9136-9141.